TSE:ONC - Oncolytics Biotech Stock Price, Forecast & News

Oncolytics Biotech's stock was trading at C$2.37 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ONC shares have decreased by 16.9% and is now trading at C$1.97. View which stocks have been mosted impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oncolytics Biotech in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Oncolytics Biotech.

Oncolytics Biotech is scheduled to release its next quarterly earnings announcement on Thursday, May 7th 2020. View our earnings forecast for Oncolytics Biotech.

Oncolytics Biotech, Inc. (TSE:ONC) announced its quarterly earnings results on Thursday, March, 5th. The company reported ($0.25) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.14) by $0.11. View Oncolytics Biotech's earnings history.

2 analysts have issued twelve-month price objectives for Oncolytics Biotech's stock. Their forecasts range from C$9.00 to C$9.00. On average, they anticipate Oncolytics Biotech's share price to reach C$9.00 in the next year. This suggests a possible upside of 356.9% from the stock's current price. View analysts' price targets for Oncolytics Biotech.

News articles about ONC stock have trended very negative this week, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Oncolytics Biotech earned a daily sentiment score of -3.7 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the next several days. View the latest news aboutOncolytics Biotech.

Some companies that are related to Oncolytics Biotech include Rafael (RFL), Emblem (EMC), Pfenex (PFNX), TELIX Pharmaceutical (TLX), Resverlogix (RVX), Helix Biopharma (HBP), Faron Pharmaceuticals Oy (FARN), Ergomed (ERGO), Bioventix (BVXP), Theratechnologies (TH), Antibe Therapeutics (ATE), Neptune Wellness Solutions (NEPT), Horizon Discovery Group (HZD), Fennec Pharmaceuticals (FRX) and CorMedix (CRMD).

Based on aggregate information from My MarketBeat watchlists, some companies that other Oncolytics Biotech investors own include Oncolytics Biotech (ONCY), Oncolytics Biotech (ONCYF), Resverlogix (RVX), Encana (ECA), Ballard Power Systems (BLDP), ProMetic Life Sciences (PLI), Bombardier (BDRBF), Husky Energy (HUSKF), Birchcliff Energy (BIR) and First Majestic Silver (FR).

Oncolytics Biotech trades on the Toronto Stock Exchange (TSX) under the ticker symbol "ONC."

Shares of ONC and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab.

One share of ONC stock can currently be purchased for approximately C$1.97.

Oncolytics Biotech has a market capitalization of C$73.63 million.  View additional information about Oncolytics Biotech.

The official website for Oncolytics Biotech is http://www.oncolyticsbiotech.com/.

Oncolytics Biotech's mailing address is 1167 Kensington Cres Nw Suite 210 Calgary Alberta Canada T2n 1X7, CALGARY, AB 00000, Canada. The company can be reached via phone at +1-403-6707380.